| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 49 | 2025 | 633 | 11.520 |
Why?
|
| Renal Insufficiency, Chronic | 32 | 2023 | 727 | 5.190 |
Why?
|
| Glomerular Filtration Rate | 29 | 2025 | 502 | 3.050 |
Why?
|
| Alberta | 40 | 2025 | 44 | 2.590 |
Why?
|
| Contrast Media | 8 | 2022 | 470 | 2.530 |
Why?
|
| Risk Assessment | 27 | 2025 | 3427 | 2.220 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2022 | 238 | 2.190 |
Why?
|
| Coronary Angiography | 7 | 2022 | 425 | 2.110 |
Why?
|
| Kidney Failure, Chronic | 16 | 2022 | 875 | 1.850 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2022 | 170 | 1.830 |
Why?
|
| Renal Replacement Therapy | 9 | 2025 | 142 | 1.770 |
Why?
|
| Renal Dialysis | 20 | 2023 | 846 | 1.760 |
Why?
|
| Postoperative Complications | 9 | 2025 | 3057 | 1.530 |
Why?
|
| Cardiac Catheterization | 6 | 2019 | 631 | 1.500 |
Why?
|
| Acute Coronary Syndrome | 5 | 2020 | 211 | 1.490 |
Why?
|
| Kidney Diseases | 10 | 2024 | 480 | 1.460 |
Why?
|
| Nephrology | 5 | 2022 | 145 | 1.310 |
Why?
|
| Practice Guidelines as Topic | 7 | 2021 | 1264 | 1.300 |
Why?
|
| Surgical Procedures, Operative | 3 | 2021 | 180 | 1.220 |
Why?
|
| Kidney | 13 | 2023 | 1352 | 1.220 |
Why?
|
| Aged | 62 | 2025 | 19520 | 1.110 |
Why?
|
| Cohort Studies | 32 | 2025 | 4769 | 1.070 |
Why?
|
| Creatinine | 14 | 2023 | 388 | 1.060 |
Why?
|
| Cardiovascular Diseases | 11 | 2024 | 1939 | 1.040 |
Why?
|
| Aged, 80 and over | 34 | 2023 | 6460 | 1.030 |
Why?
|
| Electronic Health Records | 3 | 2020 | 722 | 1.030 |
Why?
|
| Hospitalization | 17 | 2020 | 1769 | 1.010 |
Why?
|
| Middle Aged | 62 | 2025 | 26572 | 1.000 |
Why?
|
| Risk Factors | 33 | 2023 | 10242 | 0.990 |
Why?
|
| Humans | 117 | 2025 | 124020 | 0.980 |
Why?
|
| Male | 76 | 2025 | 60919 | 0.880 |
Why?
|
| Models, Biological | 3 | 2019 | 1454 | 0.870 |
Why?
|
| Female | 77 | 2025 | 66198 | 0.840 |
Why?
|
| Cause of Death | 6 | 2020 | 472 | 0.840 |
Why?
|
| Proteinuria | 6 | 2018 | 101 | 0.830 |
Why?
|
| Nurse Practitioners | 1 | 2023 | 46 | 0.820 |
Why?
|
| Prognosis | 18 | 2023 | 4607 | 0.810 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2020 | 1112 | 0.800 |
Why?
|
| Medical Audit | 1 | 2022 | 101 | 0.770 |
Why?
|
| Quality Indicators, Health Care | 3 | 2025 | 218 | 0.760 |
Why?
|
| Feedback | 1 | 2022 | 163 | 0.750 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 306 | 0.740 |
Why?
|
| Ileostomy | 1 | 2021 | 31 | 0.730 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 27 | 0.730 |
Why?
|
| Diuretics | 1 | 2021 | 171 | 0.670 |
Why?
|
| Incidence | 15 | 2023 | 3133 | 0.660 |
Why?
|
| Disease Progression | 11 | 2022 | 2046 | 0.660 |
Why?
|
| Angina Pectoris | 2 | 2016 | 57 | 0.650 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 87 | 0.640 |
Why?
|
| Coronary Artery Disease | 4 | 2022 | 767 | 0.630 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 731 | 0.620 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 222 | 0.620 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1317 | 0.590 |
Why?
|
| Models, Theoretical | 3 | 2019 | 355 | 0.580 |
Why?
|
| Arteriovenous Shunt, Surgical | 5 | 2017 | 101 | 0.570 |
Why?
|
| Aftercare | 2 | 2023 | 148 | 0.570 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 312 | 0.570 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 52 | 0.570 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 293 | 0.560 |
Why?
|
| Diabetes Mellitus | 5 | 2024 | 853 | 0.550 |
Why?
|
| Urination | 1 | 2016 | 23 | 0.540 |
Why?
|
| Mortality | 6 | 2021 | 237 | 0.530 |
Why?
|
| Comorbidity | 9 | 2018 | 1527 | 0.530 |
Why?
|
| Communication | 1 | 2020 | 504 | 0.530 |
Why?
|
| Peptide Fragments | 1 | 2020 | 777 | 0.510 |
Why?
|
| Disease Management | 1 | 2020 | 519 | 0.510 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 201 | 0.500 |
Why?
|
| Catheterization, Central Venous | 3 | 2017 | 132 | 0.490 |
Why?
|
| Adult | 36 | 2025 | 29292 | 0.480 |
Why?
|
| Mandibular Advancement | 1 | 2014 | 6 | 0.480 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 335 | 0.470 |
Why?
|
| Severity of Illness Index | 13 | 2025 | 2879 | 0.460 |
Why?
|
| Retrospective Studies | 30 | 2025 | 16242 | 0.460 |
Why?
|
| Albuminuria | 5 | 2019 | 98 | 0.460 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 509 | 0.450 |
Why?
|
| Myocardial Infarction | 4 | 2020 | 1012 | 0.440 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2021 | 127 | 0.440 |
Why?
|
| Polyuria | 1 | 2013 | 11 | 0.430 |
Why?
|
| Arthritis, Reactive | 1 | 2013 | 4 | 0.430 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 638 | 0.430 |
Why?
|
| Vertebral Artery | 1 | 2013 | 25 | 0.420 |
Why?
|
| Intensive Care Units | 6 | 2025 | 489 | 0.420 |
Why?
|
| Carotid Artery Injuries | 1 | 2013 | 40 | 0.420 |
Why?
|
| Renal Artery Obstruction | 1 | 2013 | 41 | 0.420 |
Why?
|
| Cerebral Angiography | 1 | 2013 | 102 | 0.410 |
Why?
|
| Quality of Life | 3 | 2018 | 1898 | 0.410 |
Why?
|
| Veterans Health | 1 | 2014 | 174 | 0.400 |
Why?
|
| Hyponatremia | 1 | 2013 | 72 | 0.390 |
Why?
|
| Critical Care | 2 | 2020 | 654 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 724 | 0.390 |
Why?
|
| Time Factors | 17 | 2023 | 6279 | 0.390 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 655 | 0.390 |
Why?
|
| Patient Admission | 3 | 2020 | 185 | 0.390 |
Why?
|
| Canada | 10 | 2020 | 300 | 0.380 |
Why?
|
| Hypertension | 3 | 2015 | 1317 | 0.380 |
Why?
|
| Renal Insufficiency | 3 | 2025 | 235 | 0.380 |
Why?
|
| Ischemic Attack, Transient | 3 | 2023 | 55 | 0.370 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 204 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 205 | 0.370 |
Why?
|
| Length of Stay | 5 | 2025 | 1303 | 0.370 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 216 | 0.360 |
Why?
|
| Qualitative Research | 4 | 2024 | 534 | 0.360 |
Why?
|
| Treatment Outcome | 16 | 2020 | 12267 | 0.350 |
Why?
|
| Health Care Costs | 4 | 2017 | 371 | 0.350 |
Why?
|
| Societies, Medical | 2 | 2018 | 687 | 0.340 |
Why?
|
| Patient Discharge | 4 | 2025 | 488 | 0.330 |
Why?
|
| Propensity Score | 4 | 2021 | 215 | 0.330 |
Why?
|
| Case-Control Studies | 3 | 2021 | 3269 | 0.330 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 660 | 0.330 |
Why?
|
| Kidney Function Tests | 6 | 2021 | 128 | 0.330 |
Why?
|
| Observational Studies as Topic | 2 | 2021 | 87 | 0.300 |
Why?
|
| Odds Ratio | 5 | 2021 | 1252 | 0.290 |
Why?
|
| Survival Analysis | 5 | 2020 | 1490 | 0.280 |
Why?
|
| Conservative Treatment | 2 | 2018 | 35 | 0.280 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 118 | 0.270 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 156 | 0.270 |
Why?
|
| Sick Leave | 2 | 2023 | 5 | 0.270 |
Why?
|
| Rural Health Services | 2 | 2017 | 26 | 0.260 |
Why?
|
| Depression | 1 | 2014 | 1212 | 0.260 |
Why?
|
| Recovery of Function | 4 | 2023 | 440 | 0.260 |
Why?
|
| Focus Groups | 3 | 2024 | 198 | 0.260 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 2137 | 0.250 |
Why?
|
| Fibrosis | 2 | 2018 | 428 | 0.250 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 5126 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2086 | 0.240 |
Why?
|
| Hospitals | 3 | 2023 | 390 | 0.220 |
Why?
|
| Critical Illness | 3 | 2025 | 601 | 0.220 |
Why?
|
| Bacteremia | 1 | 2008 | 405 | 0.220 |
Why?
|
| Fee-for-Service Plans | 1 | 2023 | 18 | 0.220 |
Why?
|
| Nephrologists | 1 | 2023 | 13 | 0.220 |
Why?
|
| Health Personnel | 3 | 2024 | 503 | 0.220 |
Why?
|
| Global Health | 3 | 2018 | 557 | 0.220 |
Why?
|
| Caregivers | 2 | 2019 | 557 | 0.220 |
Why?
|
| Stroke | 3 | 2023 | 973 | 0.210 |
Why?
|
| Acute Disease | 2 | 2019 | 1107 | 0.210 |
Why?
|
| Vascular Access Devices | 2 | 2013 | 35 | 0.210 |
Why?
|
| Insulins | 1 | 2022 | 17 | 0.200 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 1349 | 0.200 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2023 | 61 | 0.200 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 24 | 0.190 |
Why?
|
| Perioperative Care | 2 | 2021 | 195 | 0.190 |
Why?
|
| Age Factors | 5 | 2021 | 2807 | 0.190 |
Why?
|
| Medical Overuse | 1 | 2021 | 25 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2423 | 0.190 |
Why?
|
| Hypoglycemia | 1 | 2022 | 192 | 0.180 |
Why?
|
| Referral and Consultation | 3 | 2022 | 539 | 0.180 |
Why?
|
| Selection Bias | 1 | 2021 | 22 | 0.180 |
Why?
|
| Brain Ischemia | 1 | 2023 | 259 | 0.180 |
Why?
|
| Research Design | 2 | 2025 | 687 | 0.180 |
Why?
|
| Nitrogen Dioxide | 1 | 2020 | 18 | 0.180 |
Why?
|
| Population Dynamics | 1 | 2020 | 32 | 0.170 |
Why?
|
| Warfarin | 2 | 2023 | 119 | 0.170 |
Why?
|
| Peritoneal Dialysis | 1 | 2022 | 117 | 0.170 |
Why?
|
| Bias | 1 | 2021 | 130 | 0.170 |
Why?
|
| Forecasting | 1 | 2021 | 350 | 0.170 |
Why?
|
| Air Pollution | 1 | 2020 | 67 | 0.170 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 48 | 0.160 |
Why?
|
| Registries | 4 | 2019 | 1417 | 0.160 |
Why?
|
| Physicians | 2 | 2023 | 578 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2019 | 74 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 372 | 0.160 |
Why?
|
| Coronary Disease | 2 | 2014 | 672 | 0.160 |
Why?
|
| Patient Selection | 2 | 2014 | 689 | 0.160 |
Why?
|
| Neprilysin | 1 | 2018 | 19 | 0.160 |
Why?
|
| Colonic Polyps | 1 | 2020 | 78 | 0.160 |
Why?
|
| Valsartan | 1 | 2018 | 26 | 0.160 |
Why?
|
| Aminobutyrates | 1 | 2018 | 9 | 0.160 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 223 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2020 | 178 | 0.150 |
Why?
|
| Heart Failure | 4 | 2017 | 2288 | 0.150 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 56 | 0.150 |
Why?
|
| Curcumin | 1 | 2018 | 41 | 0.150 |
Why?
|
| Environmental Exposure | 1 | 2020 | 221 | 0.150 |
Why?
|
| Tetrazoles | 1 | 2018 | 68 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 220 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 223 | 0.150 |
Why?
|
| Risk | 3 | 2019 | 754 | 0.150 |
Why?
|
| Colonoscopy | 1 | 2020 | 234 | 0.150 |
Why?
|
| Health Status | 2 | 2018 | 371 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 171 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2018 | 265 | 0.140 |
Why?
|
| Hepatectomy | 1 | 2018 | 110 | 0.140 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 193 | 0.140 |
Why?
|
| Self-Management | 1 | 2019 | 96 | 0.140 |
Why?
|
| Survivors | 2 | 2023 | 322 | 0.140 |
Why?
|
| Gadolinium | 1 | 2018 | 104 | 0.140 |
Why?
|
| Medicine | 1 | 2018 | 96 | 0.140 |
Why?
|
| Health Services, Indigenous | 1 | 2017 | 5 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 3676 | 0.140 |
Why?
|
| Elective Surgical Procedures | 2 | 2018 | 159 | 0.140 |
Why?
|
| Indians, North American | 1 | 2017 | 59 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2023 | 770 | 0.140 |
Why?
|
| Image Enhancement | 1 | 2018 | 163 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 428 | 0.140 |
Why?
|
| Algorithms | 1 | 2023 | 1605 | 0.140 |
Why?
|
| Pyrenes | 1 | 2016 | 5 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2023 | 588 | 0.130 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1021 | 0.130 |
Why?
|
| Health Resources | 1 | 2017 | 115 | 0.130 |
Why?
|
| Databases, Factual | 4 | 2020 | 1172 | 0.130 |
Why?
|
| Urban Health Services | 1 | 2016 | 22 | 0.130 |
Why?
|
| Catheterization | 1 | 2017 | 236 | 0.130 |
Why?
|
| Catheter-Related Infections | 2 | 2017 | 130 | 0.120 |
Why?
|
| Aortic Valve | 1 | 2019 | 443 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 72 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2018 | 197 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 2863 | 0.120 |
Why?
|
| Income | 1 | 2016 | 133 | 0.120 |
Why?
|
| Lymphoma | 1 | 2018 | 322 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 159 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 156 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2020 | 640 | 0.120 |
Why?
|
| Aging | 1 | 2021 | 1167 | 0.120 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 73 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 436 | 0.110 |
Why?
|
| Pneumothorax | 1 | 2015 | 79 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 249 | 0.110 |
Why?
|
| Young Adult | 4 | 2021 | 8971 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 276 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2015 | 245 | 0.110 |
Why?
|
| Chronic Disease | 4 | 2023 | 1178 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2017 | 537 | 0.110 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 452 | 0.100 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2013 | 51 | 0.100 |
Why?
|
| Publication Bias | 1 | 2013 | 13 | 0.100 |
Why?
|
| Oxygen | 1 | 2015 | 553 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 231 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 65 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 823 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 632 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 424 | 0.090 |
Why?
|
| Mass Screening | 1 | 2017 | 781 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2013 | 186 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2010 | 50 | 0.090 |
Why?
|
| Creatine | 1 | 2010 | 41 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 606 | 0.090 |
Why?
|
| Information Services | 1 | 2009 | 21 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 930 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 567 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2022 | 210 | 0.080 |
Why?
|
| Ontario | 2 | 2023 | 65 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 78 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 175 | 0.080 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 808 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1308 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2037 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2008 | 141 | 0.070 |
Why?
|
| Logistic Models | 3 | 2020 | 1801 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1879 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2013 | 6116 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 51 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 44 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2023 | 467 | 0.070 |
Why?
|
| Survival Rate | 3 | 2018 | 2035 | 0.070 |
Why?
|
| Adolescent | 2 | 2021 | 19224 | 0.070 |
Why?
|
| Biomarkers | 4 | 2018 | 3046 | 0.060 |
Why?
|
| Ambulatory Care | 2 | 2023 | 385 | 0.060 |
Why?
|
| Anemia | 1 | 2009 | 340 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 364 | 0.060 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 221 | 0.060 |
Why?
|
| Obesity | 1 | 2015 | 2256 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2025 | 328 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 509 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 646 | 0.050 |
Why?
|
| Hypovolemia | 1 | 2022 | 11 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 83 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 120 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2016 | 303 | 0.050 |
Why?
|
| Exercise Test | 1 | 2022 | 251 | 0.050 |
Why?
|
| Patient Preference | 1 | 2022 | 117 | 0.050 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 18 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2021 | 76 | 0.040 |
Why?
|
| Health Planning | 1 | 2020 | 15 | 0.040 |
Why?
|
| Environmental Monitoring | 1 | 2020 | 65 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 69 | 0.040 |
Why?
|
| APACHE | 1 | 2019 | 53 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 310 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 635 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 318 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 274 | 0.040 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2018 | 14 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 2441 | 0.040 |
Why?
|
| United States | 2 | 2013 | 10853 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 37 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 60 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1135 | 0.040 |
Why?
|
| Telemedicine | 1 | 2024 | 429 | 0.040 |
Why?
|
| Radiologists | 1 | 2018 | 45 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 15 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 567 | 0.040 |
Why?
|
| Australasia | 1 | 2017 | 5 | 0.040 |
Why?
|
| Catheter Obstruction | 1 | 2017 | 8 | 0.040 |
Why?
|
| Manitoba | 1 | 2017 | 3 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 1682 | 0.040 |
Why?
|
| Motor Vehicles | 1 | 2017 | 9 | 0.040 |
Why?
|
| Aviation | 1 | 2017 | 8 | 0.040 |
Why?
|
| Affect | 1 | 2018 | 153 | 0.030 |
Why?
|
| Decision Making | 1 | 2022 | 654 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 51 | 0.030 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 27 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 101 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 84 | 0.030 |
Why?
|
| North America | 1 | 2017 | 239 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 111 | 0.030 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2016 | 9 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 682 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 180 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 352 | 0.030 |
Why?
|
| Palliative Care | 1 | 2020 | 425 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 313 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 329 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 427 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 29 | 0.030 |
Why?
|
| Emotions | 1 | 2018 | 348 | 0.030 |
Why?
|
| Emergencies | 1 | 2016 | 172 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 177 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1629 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 585 | 0.030 |
Why?
|
| Polysomnography | 1 | 2015 | 144 | 0.030 |
Why?
|
| Arteries | 1 | 2015 | 219 | 0.030 |
Why?
|
| Premedication | 1 | 2014 | 43 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 829 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 645 | 0.030 |
Why?
|
| Wrist Injuries | 1 | 2013 | 6 | 0.030 |
Why?
|
| British Columbia | 1 | 2013 | 8 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 42 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 38 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 2013 | 39 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 243 | 0.030 |
Why?
|
| Simvastatin | 1 | 2013 | 76 | 0.030 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 78 | 0.030 |
Why?
|
| United Kingdom | 1 | 2013 | 190 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 284 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2013 | 61 | 0.020 |
Why?
|
| Thrombosis | 1 | 2017 | 518 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 462 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1083 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1423 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1224 | 0.020 |
Why?
|
| Reagent Strips | 1 | 2011 | 11 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 436 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 177 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 723 | 0.020 |
Why?
|
| Urinalysis | 1 | 2011 | 61 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 263 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 121 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 141 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 227 | 0.020 |
Why?
|
| Heart Rate | 1 | 2013 | 584 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 1102 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 369 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 171 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 253 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 857 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 141 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1421 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 397 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 34000 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 283 | 0.020 |
Why?
|
| Child | 1 | 2022 | 24332 | 0.010 |
Why?
|